Showing 831-840 of 2783 results for "".
Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD
https://practicalneurology.com/programs/cme/safety-efficacy-and-black-box-warnings-challenges-associated-with-off-label-treatments-of-aad/27099/Tune in to learn about diagnosing and treating agitation in Alzheimer’s disease in primary care and long-term care settings.Team Approach: Enhancing Collaboration in AAD Management
https://practicalneurology.com/programs/cme/team-approach-enhancing-collaboration-in-aad-management/27097/Tune in to learn about diagnosing and treating agitation in Alzheimer’s disease in primary care and long-term care settings.Navigating Therapy: Exploring FDA-Approved Treatments for Effective AAD Care
https://practicalneurology.com/programs/cme/navigating-therapy-exploring-fda-approved-treatments-for-effective-aad-care/27101/Tune in to learn about diagnosing and treating agitation in Alzheimer’s disease in primary care and long-term care settings.Selection and Interpretation of Biomarker Tests for Alzheimer Disease
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/selection-and-interpretation-of-biomarker-tests-for-alzheimer-disease/36191/Diagnostic tests for Alzheimer disease can help guide clinical management, but results must be interpreted carefully.Blood and Cerebrospinal Fluid Biomarkers in Amyotrophic Lateral Sclerosis: Current Landscape and Potential Utility in Clinical Practice
https://practicalneurology.com/diseases-diagnoses/neuromuscular/blood-and-cerebrospinal-fluid-biomarkers-in-amyotrophic-lateral-sclerosis-current-landscape-and-potential-utility-in-clinical-practice/35542/Amyotrophic lateral sclerosis biomarkers are increasingly shaping the development of new treatments.Genetically Targeted Therapies for Inherited Neuromuscular Disorders
https://practicalneurology.com/diseases-diagnoses/neuromuscular/genetically-targeted-therapies-for-inherited-neuromuscular-disorders/31816/Targeted genetic therapies for neuromuscular disorders have ushered in a new era with still unresolved clinical, ethical, and economic questions to address.Anti-N-Methyl D Aspartate Receptor Encephalitis
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/anti-n-methyl-d-aspartate-receptor-encephalitis/31705/Encephalitis caused by antibodies to the N-methyl-D-aspartate receptor causes symptoms of movement disorders, seizure, and psychiatric disturbances.Genetic Testing & Neuromuscular Disorders
https://practicalneurology.com/diseases-diagnoses/neuromuscular/genetic-testing-neuromuscular-disorders/31920/The cost of genetic testing has decreased significantly, and the results are priceless.Tuberous Sclerosis Complex
https://practicalneurology.com/diseases-diagnoses/child-neurology/tuberous-sclerosis-complex/31942/Tuberous sclerosis complex represents the opportunity of targeted treatment resulting from identifying pathogenic gene variants for long-recognized syndromes.MS Minute: Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease/32180/MOGAD, an inflammatory demyelinating disease of the central nervous system, has some overlapping clinical features with NMOSD and MS but is a distinct entity with unique pathologic, clinical, and imaging features.